ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Atara Biotherapeutics, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 16.53% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -182.29
2
With a fall in Net Sales of -99.47%, the company declared Very Negative results in Mar 26
- NET SALES(HY) At USD 2.11 MM has Grown at -98.39%
- PRE-TAX PROFIT(Q) At USD -4.14 MM has Fallen at -108.67%
- NET PROFIT(Q) At USD -4.14 MM has Fallen at -108.67%
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -22.90%, its profits have risen by 156.4% ; the PEG ratio of the company is 0
4
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 22.36% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -22.90% returns
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Atara Biotherapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Atara Biotherapeutics, Inc.
-22.9%
-0.24
146.12%
S&P 500
22.36%
1.70
13.18%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
161.28%
EBIT Growth (5y)
16.53%
EBIT to Interest (avg)
-182.29
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.72
Sales to Capital Employed (avg)
-9.33
Tax Ratio
0.23%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
47.03%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
1
Industry P/E
Price to Book Value
-0.97
EV to EBIT
1.58
EV to EBITDA
1.51
EV to Capital Employed
-20.52
EV to Sales
0.60
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -25.88 MM
-24What is not working for the Company
NET SALES(HY)
At USD 2.11 MM has Grown at -98.39%
PRE-TAX PROFIT(Q)
At USD -4.14 MM has Fallen at -108.67%
NET PROFIT(Q)
At USD -4.14 MM has Fallen at -108.67%
CASH AND EQV(HY)
Lowest at USD 16.84 MM
INVENTORY TURNOVER RATIO(HY)
Lowest at 0 times
Here's what is working for Atara Biotherapeutics, Inc.
Operating Cash Flow
Highest at USD -25.88 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Here's what is not working for Atara Biotherapeutics, Inc.
Net Sales
At USD 2.11 MM has Grown at -98.39%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Pre-Tax Profit
At USD -4.14 MM has Fallen at -108.67%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -4.14 MM has Fallen at -108.67%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Cash and Eqv
Lowest at USD 16.84 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Inventory Turnover Ratio
Lowest at 0 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
